SCHEMBL23200340

SCHEMBL23200340

CCCCCCCCCCCC(N)(CCCCCCCCCCC)CCNCCNCCNCCNCCCN

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 2/20 0.46
RELA Q04206 4/20 0.44
DNM1 Q05193 5/20 0.41
TSHR P16473 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CA12 O43570 2/20 0.41
F13A1 P00488 2/20 0.41
CA2 P00918 2/20 0.41
CYP1A2 P05177 2/20 0.41
ALOX15 P16050 2/20 0.41
CA4 P22748 2/20 0.41
CA6 P23280 2/20 0.41
CA5A P35218 2/20 0.41
THPO P40225 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41
CA5B Q9Y2D0 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25243958 0.91 TSHR (0.48) CASP2RELADNM1TSHRALDH1A1
SCHEMBL6722894 0.83 ALDH1A1 (0.56) RELATSHRALDH1A1CYP1A2CYP2C19
SCHEMBL9178114 0.81 CA12 (0.43) CASP2DNM1TSHRALDH1A1MEN1
SCHEMBL9328367 0.81 CA12 (0.43) CASP2DNM1TSHRALDH1A1MEN1
SCHEMBL7524597 0.81 CA12 (0.37) CASP2DNM1TSHRALDH1A1MEN1
SCHEMBL23576728 0.80 DNM1 (0.57) DNM1TSHRALDH1A1MEN1KMT2A
SCHEMBL11772114 0.80 DNM1 (0.57) DNM1TSHRALDH1A1MEN1KMT2A
SCHEMBL23576181 0.80 DNM1 (0.65) DNM1TSHRALDH1A1MEN1KMT2A
SCHEMBL11775656 0.80 DNM1 (0.50) DNM1TSHRALDH1A1MEN1KMT2A
SCHEMBL5792250 0.80 DNM1 (0.50) DNM1TSHRALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4267178-A1 RNA VACCINE AGAINST SARS-COV-2 VARIANTS CureVac SE (DE) 2023-11-01 EP disclosed
EP-4146680-A1 COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA Translate Bio, Inc. (US) 2023-03-15 EP disclosed
EP-4146342-A1 IMPROVED COMPOSITIONS FOR CFTR MRNA THERAPY Translate Bio, Inc. (US) 2023-03-15 EP disclosed
WO-2022137133-A1 RNA VACCINE AGAINST SARS-COV-2 VARIANTS CUREVAC AG (DE) 2022-06-30 WO disclosed
WO-2022081548-A1 IMPROVED PROCESS OF PREPARING ICE-BASED LIPID NANOPARTICLES TRANSLATE BIO, INC. (US) 2022-04-21 WO disclosed
WO-2021226468-A1 IMPROVED COMPOSITIONS FOR CFTR MRNA THERAPY TRANSLATE BIO, INC. (US) 2021-11-11 WO disclosed
WO-2021226463-A1 COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA TRANSLATE BIO, INC. (US) 2021-11-11 WO disclosed
EP-3886897-A1 CORONAVIRUS VACCINE CureVac AG (DE) 2021-10-06 EP disclosed
WO-2021156267-A1 CORONAVIRUS VACCINE CUREVAC AG (DE) 2021-08-12 WO disclosed
WO-2021127641-A1 IMPROVED PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES TRANSLATE BIO, INC. (US) 2021-06-24 WO disclosed
EP-3802507-A1 VITAMIN CATIONIC LIPIDS Translate Bio, Inc. (US) 2021-04-14 EP disclosed